• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed—mutation rate of the marker higher than expected

BACKGROUND: In operable esophageal cancer patients, neoadjuvant therapy benefits only those who respond to the treatment. The • Pancho trial represents the first prospective randomized trial evaluating the relevance of the mark53 status for predicting the effect of two different neoadjuvant chemothe...

Full description

Saved in:
Bibliographic Details
Published in:Eur Surg
Main Authors: Kappel-Latif, Sonja, Zacherl, Johannes, Hejna, Michael, Westerhoff, Maria, Tamandl, Dietmar, Ba-Ssalamah, Ahmed, Mittlböck, Martina, Wolf, Brigitte, Wrba, Friedrich, Kührer, Irene, Pluschnig, Ursula, Schoppmann, Sebastian F., Függer, Reinhold, Zwrtek, Ronald, Glaser, Karl, Karner, Josef, Längle, Friedrich, Wenzl, Etienne, Roka, Rudolf, Öfner, Dietmar, Tschmelitsch, Jörg, Hold, Michael, Keil, Felix, Gnant, Michael, Kandioler, Daniela
Format: Artigo
Language:Inglês
Published: Springer Vienna 2018
Subjects:
Short Communication
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6290852/
https://ncbi.nlm.nih.gov/pubmed/30559831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10353-018-0527-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items